MedTrace Logo

Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

NCT02997982 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-04-03

No results posted yet for this study

Summary

This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type. It is an open pilot trial where 36 participants will receive 4 weeks of Valaciclovir treatment. Participants will be investigated using different measures before and after the treatment period.

Conditions

Interventions

DRUG

Valaciclovir 500Mg Tablet

Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.

Sponsors & Collaborators

  • Hugo Lovheim

    lead OTHER

Principal Investigators

  • Hugo Lövheim, M.D., Ph.D. · Umeå University, Umeå, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2020-03-04
Completion
2020-03-04

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02997982 on ClinicalTrials.gov